72205-40-4 Usage
Uses
Used in Pharmaceutical Industry:
(17beta)-17-hydroxy-6-methylestr-4-en-3-one is used as a medication for treating low testosterone levels in men, hormone-related issues in women, and delayed puberty in boys. It functions by replacing or supplementing the natural testosterone produced in the body.
Used in Oncology:
In certain cases, (17beta)-17-hydroxy-6-methylestr-4-en-3-one is used as a treatment for breast cancer in women. However, it is crucial to use this medication only under the guidance of a healthcare professional due to its potential side effects and the risk of abuse if not used appropriately.
Check Digit Verification of cas no
The CAS Registry Mumber 72205-40-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,2,0 and 5 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 72205-40:
(7*7)+(6*2)+(5*2)+(4*0)+(3*5)+(2*4)+(1*0)=94
94 % 10 = 4
So 72205-40-4 is a valid CAS Registry Number.
72205-40-4Relevant academic research and scientific papers
ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT
-
, (2008/06/13)
The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.
TRANSDERMAL ADMINISTRATION OF MENT
-
, (2008/06/13)
The present invention relates to transdermal dosage forms for delivery of androgens.
Method for androgen supplementation
-
, (2008/06/13)
A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.
